Table 1.
Comparisons of the Outcomes of the Women's Health Initiative -- Estrogen Plus Progestin vs Estrogen-Alone Study Arms [1,11]
| Women's Health Initiative Outcome |
Estrogen Plus Progestin Therapy (HT)[1] |
Estrogen-Alone Therapy (ET)[11] |
|---|---|---|
| Stroke | Increase | Increase |
| Hip fracture | Decrease | Decrease (except more in younger (50- to59-year age group) but small numbers of fractures, ie, 5 (placebo) vs 1 (HT); HR = 5.04, wide nCI = 0.59-43.17) |
| Coronary heart disease | Increase | Decrease in younger age (age 50-59 years HR = 0.56, nCI = 0.30-1.03); no increase in older (age 60-69 years and 70-79 years) |
| Invasive breast cancer | Increase | No increase |
| Venous thromboembolism | Increase | Increase |
| Colorectal cancer | Decrease | Decrease in younger age group (50 to 59), but increase in older (age 70 to 79 years HR = 2.09, nCI = 1.08-4.04) |
| Global index | Increase | No increase |
| Mortality | No increase | No increase |
Note: Therapy is compared with placebo in healthy postmenopausal women.HR = hazard ratio; nCI = nominal confidence interval